Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
James J. Peters VA Medical Center, Bronx, New York, USA.
Alzheimers Dement. 2022 Dec;18(12):2582-2592. doi: 10.1002/alz.12623. Epub 2022 Feb 25.
Racial/ethnic disparities in anti-dementia medications use in longitudinally followed research participants are unclear.
The study included initially untreated participants followed in National Alzheimer's Coordinating Center Uniform Data Set who were ≥65 at baseline with Alzheimer's disease dementia.
Outcomes for acetylcholinesterase inhibitor (AChEI) treatment included (1) any new AChEI treatment during follow-up, and (2) persistence of treatment during follow-up categorized into: intermittent treatment (< 50% follow-ups reporting treatment), persistent (≥50% follow-ups), and always treated. Outcomes for memantine treatment were similarly constructed.
Controlling for participant characteristics, Black and Hispanic participants remained less likely than White participants to report any new AChEI or memantine treatment during follow-up. Among those who reported new treatment during follow-up, both Black and Hispanic participants were less likely than White participants to be persistently treated with AChEI and memantine.
Substantial racial/ethnic treatment disparities remain in controlled settings of longitudinal research in which participants have access to dementia experts, suggesting wider disparities in the larger community.
在纵向随访研究参与者中，抗痴呆药物使用的种族/民族差异尚不清楚。
该研究纳入了最初未经治疗、在国家阿尔茨海默病协调中心统一数据集中随访的参与者，他们在基线时≥65 岁，患有阿尔茨海默病痴呆症。
在控制了参与者特征后，黑人和西班牙裔参与者报告在随访期间接受任何新的乙酰胆碱酯酶抑制剂（AChEI）或美金刚治疗的可能性仍低于白种人参与者。在报告新治疗的参与者中，黑人和西班牙裔参与者与白种人参与者相比，持续接受 AChEI 和 memantine 治疗的可能性均较低。
在参与者可以获得痴呆症专家治疗的纵向研究的对照环境中，仍然存在大量的种族/民族治疗差异，这表明在更大的社区中存在更广泛的差异。
